Assertio Reports Second Quarter 2025 Financial Results

(NASDAQ:ASRT), Second Quarter Total Net Product Sales of $28.8 Million, Cash and Investments Increase to $98.2 Million Narrows Guidance on Continued Progress Implementing Long-Term Business Strategy LAKE FOREST, Ill., Aug. 11, 2025 (GLOBE NEWSWIRE) — Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed […]

PennantPark Investment Corporation Announces Financial Results for the Quarter Ended June 30, 2025

PennantPark Investment Corporation Announces Financial Results for the Quarter Ended June 30, 2025 GlobeNewswire August 11, 2025 MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) — PennantPark Investment Corporation (NYSE: PNNT) announced today its financial results for the third quarter ended June 30, 2025. HIGHLIGHTS Quarter ended June 30, 2025 (unaudited)($ in millions, except per share amounts)

ACV Announces Second Quarter 2025 Results

(NYSE:ACVA), Second quarter revenue of $194 million Second quarter GAAP net income (loss) of ($7) million Second quarter non-GAAP net income of $12 million Second quarter Adjusted EBITDA of $19 million Expects 2025 revenue of $765 million to $775 million, growth of 20% to 22% YoY, GAAP net income (loss) of ($51) million to ($47)

Life360 Names COO Lauren Antonoff as Chief Executive Officer

(ASX – Trade24:360.AX),(NASDAQ:LIF), Co-Founder Chris Hulls will serve as Executive Chairman of the Board Planned leadership succession signals continued investment in product innovation and growth SAN FRANCISCO, Aug. 11, 2025 (GLOBE NEWSWIRE) — Life360 (Nasdaq: LIF), the category-defining family connection and safety company, today announced that Lauren Antonoff has been promoted to Chief Executive Officer

Sana Biotechnology Reports Second Quarter 2025 Financial Results and Business Updates

(NASDAQ:SANA), Presented positive 6-month clinical results of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome immune recognition, while continuing to function and persist with stable C-peptide New England Journal of Medicine published positive 12-week clinical results of the type 1 diabetes study Recent FDA INTERACT meeting increases confidence

PennantPark Floating Rate Capital Ltd. Announces Financial Results for the Third Quarter Ended June 30, 2025

(NYSE:PFLT),(TASE:PFLT.TA), MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) — PennantPark Floating Rate Capital Ltd. (NYSE: PFLT) announced today its financial results for the third fiscal quarter ended June 30, 2025. HIGHLIGHTSQuarter ended June 30, 2025 (Unaudited)($ in millions, except per share amounts) Assets and Liabilities: Investment portfolio (1) $ 2,403.5 Net assets $ 1,087.5 Net asset

Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

(NASDAQ:CAPR), Type A meeting with U.S. FDA scheduled to discuss Deramiocel BLA and path toward potential approval Capricor seeks to resubmit its BLA based on its existing dataset, with HOPE-3 data (expected in Q4 2025) potentially serving as supportive and confirmatory evidence, pending regulatory guidance All 483 observations noted in the Pre-License Inspection have been

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Second Quarter 2025 Financial Results on August 14, 2025

(NasdaqGM:NRXP), WILMINGTON, Del., Aug. 11, 2025 (GLOBE NEWSWIRE) — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced that it will release its second quarter 2025 financial results after the market closes on Thursday, August 14, 2025 via press release, which will be available on the Company's website at

Metagenomi Appoints Laurence Reid, PhD to its Board of Directors

(NASDAQ:MGX),(NasdaqGM:KALV), EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) — Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced the appointment of Laurence Reid, PhD, to its Board of Directors. “We are delighted to welcome Dr. Reid to our

Scroll to Top